Las drogas Inhibidoras de los Puntos de Control Inmunológico para tratamiento del cáncer. Un Nuevo reto para la Onco-Reumatología de Cuba

Gil Alberto Reyes Llerena

Las drogas Inhibidoras de los Puntos de Control Inmunológico para tratamiento del cáncer. Un Nuevo reto para la Onco-Reumatología de Cuba

Gil Alberto Reyes Llerena

Texto completo:

PDF

Resumen

En los últimos años se ha ido desarrollando una nueva disciplina médica denominada Onco-Reumatología. Está considerada un punto de unión entre la Oncología y la Reumatología, basada en los resultados de las investigaciones acerca de los complejos mecanismos patogénicos, aspectos clínicos y estrategias terapéuticas que involucran a los pacientes con enfermedades autoimmune reumáticas y procesos tumorales malignos

Palabras clave

drogas Inhibidoras de los Puntos de Control Inmunológico; tratamiento del cáncer; Onco-Reumatología de Cuba

Referencias

Zoltán Szekanecza, Izabella Gomeza,g, Boglárka Soósa, Levente Bodokia, Szilvia Szamosia, Csilla Andrásd, Balázs Juhászd, László Váróczyb, Péter Antal-Szalmáse, Péter Szodorayc,j, Nóra Bittnerf et al. Eight pillars of Oncorheumatology: Cross-roads between malignancies and musculoskeletal diseases. Autoimmunity Review,19 (2020):102658.

Giat E, Ehrenfeld M, Shoenfeld Y. Cancer and autoimmune diseases. Autoimmun Rev 2017;16:1049–57.

Ami A. Shah, Livia Casciola-Rosen, and Antony Rosen. Cancer-Induced Autoimmunity in the Rheumatic Diseases. Review. Arthritis & Rheumatology. Vol. 67, No. 2, February 2015, pp 317–326 DOI 10.1002/art.38928 © 2015 .

Carl Turesson and Eric L. Matteson. Review Malignancy as a comorbidity in rheumatic diseases. Rheumatology 2013;52:514. rheumatology/kes.

Klavdianou K, Melissaropoulos K, Filippopoulou A, Daoussis D. Should we be Afraid of Immune Check Point Inhibitors in Cancer patients with Pre-existing Rheumatic Diseases?. Mediterr J Rheumatol 2021;32(3):218-26.

Cutolo M, Paolino S, Pizzorni C. Possible contribution of chronic inflammation in the induction of cancer in rheumatic diseases. Clin Exp Rheumatol 2014;32:839–47.

Saya Jacob, MD; Kian Rahbari, BS; Kyle Tegtmeyer, BS; Jeffrey Zhao, BA; Steven Tran, BS; Irene Helenowski, PhD; Hui Zhang, PhD; Theresa Walunas; John Varga; Jane Dematte; Victoria Villaflor. Oncology Lung Cancer Survival in Patients With Autoimmune Disease. JAMA Network Open. 2020;3(12):e2029917. doi:10.1001/jamanetworkopen.2020.29917

Jian Wen, Han Ouyang, Ru Yang, Lin Bo, Yi Zhang, Mei Tang & Zhichun Liu; Malignancy dominated with rheumatic manifestations: A retrospective single-center analysis Scientif Report. (2018) 8:1786 | DOI:10.1038/s41598-018-20167

Kaitlin R McCarter, Senada Arabelovic, Xiaosong Wang, Taylor Wolfgang, Kazuki Yoshida , Grace Qian , Emily N Kowalski , Kathleen M M Vanni, Nicole R LeBoeuf , Elizabeth I Buchbinder , Lydia Gedmintas, Lindsey A MacFarlane, Deepak A Rao , Nancy A Shadick, Ellen M Gravallese, Jeffrey A Sparks. Immunomodulator use, risk factors and management of flares, and mortality for patients with pre-existing rheumatoid arthritis after immune check point inhibitors for cancer. Semin arthritis reum. 2024 Feb:64:152335. doi: 10.1016/j.semarthrit.2023.1

Berna C. Özdemir · Cristina Espinosa da Silva · Dimitri Arangalage · Pierre Monney · Sabina A. Guler · Uyen Huynh Do · Guido Stirnimann · et.al.,Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune related adverse events among cancer patients. .Cancer Immunology, Immunotherapy (2023) 72:1991–2001 https://doi.org/10.1007/s00262-023-03436-0

Menglu Pan , Huanhuan Zhao , Ruimin Jin , Patrick S. C. Leung and Zongwen Shuai. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future. Frontiers in Inmunology. Review Published 06 April 2023. DOI 10.3389/fimmu.2023.1156212

Konstantinos Melissaropoulos , Kalliopi Klavdianou, Alexandra Filippopoulou Fotini Kalofonou, Haralabos Kalofonos and Dimitrios Daoussis. Review. Rheumatic Manifestations in patients treated with Immune Checkpoint Inhibitors. Int. J. Mol. Sci. 2020, 21, 3389; doi:10.3390/ijms21093389 www.mdpi.com/journal/ijms

Laura C. Capelli, Julie R. Bhramer, Patrick M. Forde, Dun T Le, Evan J lipson Jarushka Jainodo, Lei Zheng, Clifton O. Bigham, Ami A. Shad, Lei Zheng. Clinical presentation of immune checkpoint inhibitor-induced inflammatory arthritis differs by immunotherapy regimen. Seminars in Arthritis and Rheumatism. Volume 48, Issue 3, December 2018, Pages 553-557.

Li Zeng Gang Ma, Kai Chen and Qiao Zhou Zeng L, Ma G, Chen K and Zhou Q (2023). Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors. Front. Immunol. 14:1242336. doi: 10.3389/fimmu.2023.1242336

Amanda Lusa, Carolina Alvarez, Shruti Saxena Beem, Todd A. Schwartz and Rumey Ishizawar. Immune-related adverse events in patients with pre-existing autoimmune rheumatologic disease on immune checkpoint inhibitor therapy. BMC Rheumatology (2022) 6:64 https://doi.org/10.1186 /s41927-022-00297-5

Szekanecza Z. autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment, hung. Medizinhist J 2019;160:887–95.

Maria Cecilia Garbarino, Natalia Manzano, Osvaldo Messina, Marcelo Zylberman. Rheumatological adverse events secondary to immune checkpoint inhibitors Reumatología Clínica vol 119, 4 (2023): 215-222. https://doi.org /10.1016/ j.reuma.2022.09.004

Si-Yang Liu, Yi-Long Wu. An immunological storm for cancer therapy: 2018 Nobel Prize in Physiology or Medicine. Science Bulletin 63 (2018) 1608–1610 https://doi.org/10.1016/j.scib.2018.11.023 2095-9273/

Anne Madroszyk. Musculoskeletal immune-related adverse events in 927 patients treated with immune checkpoint inhibitors for solid cancer. Joint Bone Spine. Volume 90, Issue 1, January 2023, 105457. https://doi.org/10.1016/j.jbspin.2022.105457

Gil Alberto Reyes Llerena. Editorial. El reto del internista ante las enfermedades autoinmune reumáticas . The Challenge Faced by Internists in Rheumatological Autoimmune Diseases, Revista Cubana de Medicina. 2023 (Oct-Dic); 62(4):e3478. https://orcid.org/0000-0001-7749-5652

Enlaces refback

No hay ningún enlace refback.

Esta obra está bajo una licencia de Creative Commons Reconocimiento-NoComercial 4.0 Internacional.